ArticleScientific reports2026
Cancer-associated fibroblasts -derived Tenascin-C activates the Hippo/TAZ pathway to suppress ferroptosis and confer cisplatin resistance in esophageal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aims to investigate the mechanistic role of fibronectin (TNC) secreted by cancer-associated fibroblasts (CAFs) and its impact on cisplatin (DDP) sensitivity in esophageal squamous cell carcinoma (ESCC). Through in vitro cell experiments and analyses of clinical specimens, we observed that elevated levels of CAF-derived TNC significantly downregulate TAZ (WWTR1) expression in cancer cells and inhibit ferroptosis, thereby contributing to increased resistance to cisplatin. Mechanistically, TNC exerts its effects by activating the Hippo signaling pathway, which suppresses TAZ expression, reduces intracellular iron accumulation, and decreases the expression of ferroptosis-related proteins, ultimately diminishing drug sensitivity. Intervention experiments demonstrated that knocking down TNC or restoring TAZ expression enhances ferroptosis and augments cisplatin-induced cytotoxicity. Clinically, high expression levels of FAP and TNC are correlated with adverse pathological features, indicating that the TNC/TAZ axis may serve as a potential biomarker and therapeutic target for modulating chemosensitivity in ESCC. Our findings reveal a critical role for CAF-derived TNC in regulating ferroptosis and chemoresistance, providing new insights into therapeutic strategies aimed at improving treatment outcomes for ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.